Optimizing the management of renal anemia: Challenges and new opportunities

Kidney International

Volumn 74, Issue SUPPL. 111, 2008, Pages

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

Anemia; Chronic kidney disease; Continuous erythropoiesis receptor activator; Erythropoiesis stimulating agents; Erythropoietin; Hematide

Indexed keywords

ABSEAMED; BINOCRIT; CNTO 530; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; EPOETIN OMEGA; EPOETIN ZETA; ERYTHROPOIETIN; HEMOGLOBIN; HX 575; HYBRID PROTEIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RETACRIT; SILAPO; UNCLASSIFIED DRUG; ANTIANEMIC AGENT; MACROGOL DERIVATIVE; PEPTIDE; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANEMIA; BIOEQUIVALENCE; BLOOD TRANSFUSION; CHO CELL; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; ERYTHROPOIESIS; GENE EXPRESSION; GLYCOSYLATION; HUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; CHRONIC DISEASE; KIDNEY DISEASE; REVIEW;

ANEMIA; CHRONIC DISEASE; HEMATINICS; HUMANS; KIDNEY DISEASES; PEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 61549126333     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.525     Document Type: Conference Paper

References (49)

1. Mcclellan WM, Aronoff SL, Bolton WK. The prevalence of anaemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501-1510.
2. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study DOPPS). Nephrol Dial Transplant 2004; 19: 121-132.
3. Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985; 82: 7580-7584.
4. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178.
5. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
6. Storring PL, Tiplady RJ, Gaines Das RE et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998; 100: 79-89.
7. Powell JS, Berkner KL, Lebo RV et al. Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA 1986; 83: 6465-6469.
8. Nimtz M, Martin W, Wray V et al. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur J Biochem 1993; 213: 39-56.
9. Deicher R, Horl WH. Differentiating factors between erythropoiesis- stimulating agents: a guide to selection for anaemia of chronic kidney disease. Drugs 2004; 64: 499-509.
10. Kwan JT, Pratt RD, The Epoetin Delta Study Group. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients. Curr Med Res Opin 2007; 23: 307-311.
11. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21(Suppl 5): v13-v16.
12. Egrie JC, Browne KJ. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16(Suppl 3): 3-13.
13. Locatelli F, Olivares J, Walker R et al. European/Australian NESP 980202 Study Group. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60: 741-747.
14. Locatelli F, Canaud B, Giacardy F et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369.
15. Vanrenterghem Y, Barany P, Mann JF et al. European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167-2175.
16. Mann J, Kessler M, Villa G et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. Clin Nephrol 2007; 67: 140-148.
17. Aarup M, Bryndum J, Dieperink H et al. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant 2006; 21: 1312-1316.
18. Brandt M, Lazendörfer M, Frische J et al. Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Nephrol Dial Transplant 2006; 21(Suppl 4): iv9 (Abstract SO018).
19. Locatelli F, Villa G, De Francisco ALM et al. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis. Curr Med Res Opin 2007; 23: 969-979.
20. Levin NW, Fishbane S, Cañedo FV et al. MAXIMA study investigators: intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370: 1415-1421.
21. Macdougall IC, Walker R, Provenzano R et al. C.E.R.A. (continuous erythropoietin receptor activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. J Am Soc Nephrol 2006; 17: 619A (Abstract SA-PO208).
22. Drueke TB, Locatelli F, Clyne N, et al., CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
23. Singh AK, Szczech L, Tang KL, et al., CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
24. Sytkowski AJ, Lunn ED, Davis KL et al. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci USA 1998; 95: 1184-1188.
25. Dalle B, Henri A, Rouyer-Fessard P et al. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood 2001; 97: 3776-3782.
26. Fares F, Ganem S, Hajouj T et al. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. Endocrinology 2007; 148: 5081-5087.
27. Schriebl K, Trummer E, Lattenmayer C et al. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expr Purif 2006; 49: 265-275.
28. Way JC, Lauder S, Brunkhorst B et al. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng Des Sel 2005; 18: 111-118.
29. Dumont JA, Bitonti AJ, Clark D et al. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med 2005; 18: 294-303.
30. Kochendoerfer GG, Chen SY, Mao F et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science 2003; 299: 884-887.
31. Chen SY, Cressman S, Mao F et al. Synthetic erythropoietic proteins: tuning biological performance by site-specific polymer attachment. Chem Biol 2005; 12: 371-383.
32. Coscarella A, Liddi R, Di Loreto M et al. The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 1998; 10: 964-969.
33. Fan Q, Leuther KK, Holmes CP et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34: 1303-1311.
34. Woodburn KW, Fan Q, Winslow S et al. Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol 2007; 35: 1201-1208.
35. NCT00314795 registered on the clinicaltrial.gov website.
36. Bugelski PJ, Capocasale RJ, Makropoulos D et al. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J Biotechnol 2008; 134: 171-180.
37. Safran M, Kim WY, O'Connell F et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA 2006; 103: 105-110.
38. Dame C, Sola MC, Lim K-C et al. Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 2004; 279: 2955-2961.
39. Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997; 89: 1430-1439.
40. Nakano Y, Imagawa S, Matsumoto K et al. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anaemia of chronic disease. Blood 2004; 104: 4300-4307.
41. Klingmuller U, Lorenz U, Cantley LC et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80: 729-738.
42. Wickrema A, Chen F, Namin F et al. Defective expression of the SHP-1 phosphatase in polycythemia vera. Exp Hematol 1999; 27: 1124-1132.
43. Akagi S, Ichikawa H, Okada T et al. The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J Am Soc Nephrol 2004; 15: 3215-3224.
44. Sebestyén MG, Hegge JO, Noble MA et al. Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther 2007; 18: 269-285.
45. Fattori E, Cappelletti M, Zampaglione I et al. Gene electro-transfer on an improved erythropoietin plasmid in mice and non-human primates. J Gene Med 2005; 7: 228-236.
46. Eliopoulos N, Gagnon RF, Francois M et al. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol 2006; 17: 1576-1584.
47. Oh TK, Quan GH, Kim HY et al. Correction of anemia in uremic rats by intramuscular injection of lentivirus carrying an erythropoietin gene. Am J Nephrol 2006; 26: 326-334.
48. Kakeda M, Hiratsuka M, Nagata K et al. Human artificial chromosome (HAC) vector provides long-term therapeutic transgene expression in normal human primary fibroblasts. Gene Ther 2005; 12: 852-856.
49. Heifets M, Dougherty FC, Beyer U et al. on behalf of the PROTOS, MAXIMA, STRIATA and RUBRA study investigators. Hemoglobin (Hb) decline after withholding CERA. Administration is not influenced by the long half life of CERA. Abstract presented at the World Congress of Nephrology, 2007.